Related Experiment Videos
The climacteric and gynaecological cancers.
L Zichella1, R Brunelli, C De Angelis
1Ist Institute of Obstet. Gynec. La Sapienza University - Rome, Italy.
European Journal of Gynaecological Oncology
|January 1, 1989
Summary
The climacteric period increases risks for genital and mammary neoplasias, potentially due to hormonal changes. Combined estrogen-progesterone therapy appears safe and beneficial for women.
Area of Science:
- Gynecology
- Oncology
- Epidemiology
Background:
- The climacteric (menopausal transition) is associated with increased risk for genital and mammary neoplasias.
- Hyperestrogenic conditions during climacteric may promote neoplastic growth in the genital tract.
- Reproductive history, rather than perimenopausal hormones, appears more critical for breast cancer risk.
Purpose of the Study:
- To investigate the relationship between the climacteric period and the risk of developing genital and mammary neoplasias.
- To evaluate the safety and efficacy of different hormone replacement therapies (HRT) in postmenopausal women.
Main Methods:
- Analysis of epidemiologic data on climacteric women.
- Review of hormonal effects of estrogen and combined estrogen-progesterone therapies on reproductive organs and breast tissue.
Main Results:
- Estrogen replacement therapy (ERT) shows potential risks primarily for the endometrium.
- ERT demonstrates minimal to no significant effect on the ovary and breast.
- Combined estrogen-progesterone therapy (EPT) appears to offer benefits and demonstrates a high safety profile.
Conclusions:
- The climacteric period presents elevated risks for gynecologic and breast cancers.
- Estrogen replacement therapy warrants caution due to endometrial risks.
- Combined estrogen-progesterone therapy is suggested as a safe and potentially beneficial option for managing menopausal symptoms and associated risks.